NTHI — NEONC TECHNOLOGIES HOLDINGS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1979414 ·
Last close
$4.33
Market Cap
$124.92M
52W High
$11.38
52W Low
$2.50
ADV30
173,998
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,739,306 | -4,440,209 | 9,304,284 | 6,166,342 | 22,476,599 |
| Jun 2026 | 0 | — | -13,587,109 | -14,240,044 | 5,231,792 | 1,973,420 | 23,761,103 |
| Mar 2026 | 0 | — | -7,008,539 | -8,819,932 | 3,330,161 | 138,601 | 16,561,326 |
| Dec 2025 | 0 | — | -13,625,675 | -15,524,104 | 2,823,634 | 58,729 | 20,331,363 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,156,677
Investing CF
—
Financing CF
$23,505,056
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.71
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-135,814,631
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-43,836,111
Pretax Income TTM
$-47,200,000
Interest Exp TTM
$3,363,889
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$39,990
EBITDA
—
Free Cash Flow
$5,401,299
Enterprise Value
$81,030,632
Total Cash
$1,973,420
Total Debt
$328,217
Shares Out
28,850,588
Trailing EPS
$-1.95
Book Value
$-0.81
ROE
—
ROA
-635.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 39,990 | -58,169,198 | -62,146,210 | 2,823,634 | 20,331,363 | -17,507,729 | -20,363,948 |
| Dec 2024 | 83,000 | -7,142,522 | -11,898,464 | 3,417,241 | 8,922,202 | -5,504,961 | -4,213,916 |
| Dec 2023 | 70,462 | -8,097,669 | -14,921,065 | 1,265,376 | 15,253,629 | -13,988,253 | -1,880,012 |
| Dec 2022 | 20,000 | -2,837,604 | -3,046,757 | 728,682 | 2,304,093 | -1,575,411 | -881,736 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-41,524,029
OpCashFlow TTM
—
Assets (Latest)
$5,231,792
Forward EPS
$-1.09
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGNX | MACROGENICS INC | $131.01M | $2.05 | — |
| MSLE | Satellos Bioscience Inc. | $131.54M | $6.20 | — |
| MENS | Jyong Biotech Ltd. | $133.62M | $1.80 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $116.37M | $40.49 | — |
| UPB | Upstream Bio, Inc. | $115.10M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
2026-11-17 13:00 · Yahoo
NeOnc CEO Amir Heshmatpour’s 2026 Open-Market Share Purchases Exceed $1.5 Million
2026-11-16 13:00 · Yahoo
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
2026-11-11 13:00 · Yahoo
NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases
2026-11-10 15:38 · Yahoo
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-11-05 14:00 · Yahoo
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
2026-11-02 13:00 · Yahoo
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
2026-10-22 12:00 · Yahoo
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
2026-10-21 14:17 · Yahoo
NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
2026-10-21 12:00 · Yahoo
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
2026-10-16 13:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.